A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases

Trial Profile

A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Paclitaxel
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Jul 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 24 Jul 2014 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top